P01AG090268
Project Grant
Overview
Grant Description
SORL1 AND ITS INVOLVEMENT IN ALZHEIMER'S DISEASE PATHOGENESIS AND PATHOPHYSIOLOGY - OVERALL PROJECT SUMMARY/ABSTRACT SORL1 IS EMERGING AS ONLY THE 4TH GENE THAT IS CONSIDERED CAUSAL IN ALZHEIMER’S DISEASE. NEW INSIGHT SHOWS HOW SORL1 FUNCTIONS BY INTERACTING WITH THE RETROMER TRAFFICKING COMPLEX, HOW DISRUPTING THIS INTERACTION CAN MEDIATE THE DISEASE’S CARDINAL PATHOLOGIES, AND HOW SORL1-RETROMER DISRUPTIONS HAVE BEEN COMMONLY LINKED TO LATE-ONSET AD. THE PROBLEM IS THAT THERE ARE HUNDREDS OF DISEASE-ASSOCIATED SORL1 VARIANTS, AND THE PATHOGENESIS AND PATHOPHYSIOLOGY OF MOST OF THEM REMAIN UNKNOWN. THE PPG’S OVERALL GOAL IS TO SOLVE THIS PROBLEM BY RELYING ON A RECENTLY DEVELOPED PRIORITIZATION FRAMEWORK DESIGNED TO IDENTIFY SORL1 MISSENSE VARIANTS MOST LIKELY TO BE PATHOGENIC. THE FRAMEWORK USES THE KNOWN EFFECTS OF VARIANTS IN PROTEINS WITH SIMILAR DOMAINS TO ASSESS THE LIKELIHOOD THAT A SORL1 VARIANT IN A HOMOLOGOUS DOMAIN MAY LEAD TO A SPECIFIC DEFECT. AS ALSO DETAILED IN THE APPLICATION, PROVISIONAL SUPPORT FOR THIS FRAMEWORK’S CAPABILITIES IS PROVIDED BY RECENT STUDIES. THE PPG’S OVERALL APPROACH IS TO RELY ON A UNIFIED SET OF SORL1 VARIANTS THAT THE FRAMEWORK PREDICTS TO BE PATHOGENIC. THE PPG’S CORES WILL PROVIDE BIOMATERIALS PLUS CLINICAL AND CELLULAR EVIDENCE ON THE PATHOGENICITY OF EACH VARIANT, USING BOTH STANDARD AND NOVEL READOUTS. THE PROJECTS WILL COLLECTIVELY PROBE THE PATHOPHYSIOLOGY OF EACH OF THE PATHOGENIC VARIANTS--- INTEGRATING STRUCTURAL, CELLULAR, ANATOMICAL, AND BIOFLUIDIC INVESTIGATIONS. THE PPG’S CORES AND PROJECTS WILL HAVE HYPOTHESIS-DRIVEN AIMS, BUILDING ON EXISTING EVIDENCE ABOUT HOW SORL1 LOSS-OF-FUNCTION VARIANTS AFFECT THE RETROMER-DEPENDENT ENDOSOMAL RECYCLING PATHWAY, BUT THEY WILL ALSO HAVE UNBIASED AIMS DESIGNED TO EXPLORE AND EXPAND THE MECHANISTIC UNDERSTANDING INTO HOW SORL1 MIGHT DRIVE AND/OR MODULATE AD PATHOLOGY. COLLECTIVELY, BY CLARIFYING SORL1’S LOSS-OF-FUNCTION, THE PPG PROMISES TO HAVE HIGH AND BROAD TRANSLATIONAL IMPACT. ULTIMATELY, BY COMPLETING THE PROPOSED STUDIES, THE PPG WILL INFORM ON DEVELOPING NOVEL THERAPEUTIC INTERVENTIONS, NOT ONLY FOR THE ESTIMATED 3% OF ALL AD PATIENTS WHO ARE THOUGHT TO HARBOR A PATHOGENIC SORL1 VARIANT, BUT ALSO FOR LATE-ONSET DISEASE MORE GENERALLY.
Funding Goals
TO ENCOURAGE BIOMEDICAL, SOCIAL, AND BEHAVIORAL RESEARCH AND RESEARCH TRAINING DIRECTED TOWARD GREATER UNDERSTANDING OF THE AGING PROCESS AND THE DISEASES, SPECIAL PROBLEMS, AND NEEDS OF PEOPLE AS THEY AGE. THE NATIONAL INSTITUTE ON AGING HAS ESTABLISHED PROGRAMS TO PURSUE THESE GOALS. THE DIVISION OF AGING BIOLOGY EMPHASIZES UNDERSTANDING THE BASIC BIOLOGICAL PROCESSES OF AGING. THE DIVISION OF GERIATRICS AND CLINICAL GERONTOLOGY SUPPORTS RESEARCH TO IMPROVE THE ABILITIES OF HEALTH CARE PRACTITIONERS TO RESPOND TO THE DISEASES AND OTHER CLINICAL PROBLEMS OF OLDER PEOPLE. THE DIVISION OF BEHAVIORAL AND SOCIAL RESEARCH SUPPORTS RESEARCH THAT WILL LEAD TO GREATER UNDERSTANDING OF THE SOCIAL, CULTURAL, ECONOMIC AND PSYCHOLOGICAL FACTORS THAT AFFECT BOTH THE PROCESS OF GROWING OLD AND THE PLACE OF OLDER PEOPLE IN SOCIETY. THE DIVISION OF NEUROSCIENCE FOSTERS RESEARCH CONCERNED WITH THE AGE-RELATED CHANGES IN THE NERVOUS SYSTEM AS WELL AS THE RELATED SENSORY, PERCEPTUAL, AND COGNITIVE PROCESSES ASSOCIATED WITH AGING AND HAS A SPECIAL EMPHASIS ON ALZHEIMER'S DISEASE. SMALL BUSINESS INNOVATION RESEARCH (SBIR) PROGRAM: TO EXPAND AND IMPROVE THE SBIR PROGRAM, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, TO INCREASE SMALL BUSINESS PARTICIPATION IN FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION. SMALL BUSINESS TECHNOLOGY TRANSFER (STTR) PROGRAM: TO STIMULATE AND FOSTER SCIENTIFIC AND TECHNOLOGICAL INNOVATION THROUGH COOPERATIVE RESEARCH DEVELOPMENT CARRIED OUT BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO FOSTER TECHNOLOGY TRANSFER BETWEEN SMALL BUSINESS CONCERNS AND RESEARCH INSTITUTIONS, TO INCREASE PRIVATE SECTOR COMMERCIALIZATION OF INNOVATIONS DERIVED FROM FEDERAL RESEARCH AND DEVELOPMENT, AND TO FOSTER AND ENCOURAGE PARTICIPATION OF SOCIALLY AND ECONOMICALLY DISADVANTAGED SMALL BUSINESS CONCERNS AND WOMEN-OWNED SMALL BUSINESS CONCERNS IN TECHNOLOGICAL INNOVATION.
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
New York
United States
Geographic Scope
State-Wide
Related Opportunity
The Trustees Of Columbia University In The City Of New York was awarded
Sorl1 Variants in Alzheimer's: Pathogenesis Study
Project Grant P01AG090268
worth $3,184,272
from National Institute on Aging in September 2025 with work to be completed primarily in New York United States.
The grant
has a duration of 4 years 8 months and
was awarded through assistance program 93.866 Aging Research.
The Project Grant was awarded through grant opportunity NIA Program Project Applications (P01 Clinical Trial Optional).
Status
(Ongoing)
Last Modified 9/24/25
Period of Performance
9/15/25
Start Date
5/31/30
End Date
Funding Split
$3.2M
Federal Obligation
$0.0
Non-Federal Obligation
$3.2M
Total Obligated
Activity Timeline
Additional Detail
Award ID FAIN
P01AG090268
SAI Number
P01AG090268-2874230113
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Private Institution Of Higher Education
Awarding Office
75NN00 NIH National Insitute on Aging
Funding Office
75NN00 NIH National Insitute on Aging
Awardee UEI
QHF5ZZ114M72
Awardee CAGE
3FHD3
Performance District
NY-90
Senators
Kirsten Gillibrand
Charles Schumer
Charles Schumer
Modified: 9/24/25